Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Norketotifen in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Subjects

In brief

This is a Phase 1, single-center, double-blind, randomized, placebo-controlled, 2-part, single ascending dose and multiple dose cohort study of orally administered Norketotifen (NKT) in healthy subjects.

Key facts

Study ID

NCT03712163

Run by

Emergo Therapeutics, Inc.

People needed

74

Starts

2018-10-15

Expected to finish

2019-03-14

Last updated by the study team

2019-03-21

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

• Worldwide Clinical Trials — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.